ABSTRACT -A validation study of an in vitro skin irritation testing method using a reconstructed human skin model has been conducted by the European Centre for the Validation of Alternative Methods (ECVAM), and a protocol using EpiSkin (SkinEthic, France) has been approved. The structural and peralong with the approval. We have performed several evaluations of the new reconstructed human epiderthe ECVAM Performance Standards. We selected 19 materials (nine irritants and ten non-irritants) available in Japan as test chemicals among the 20 reference chemicals described in the ECVAM Performance Standard. A test chemical was applied to the surface of the LabCyte EPI-MODEL for 15 min, after which it was completely removed and the model then post-incubated for 42 hr. Cell viability was measured by -centration in the culture supernatant after post-incubation was measured to provide a complementary evaluation of skin irritation. Evaluation of the 19 test chemicals resulted in 79% accuracy, 78% sensitivity and in vitro skin irritancy of the LabCyte EPI-MODEL correlates highly with in vivo skin irritation. These results suggest that LabCyte EPI-MODEL is applicable to the skin irritation testing protocol set out in the ECVAM Performance Standards.
INTRODUCTION
Trials to replace the Draize skin irritation test on rabbits in vivo, carried out according to the OECD TG404 test guidelines (OECD, 2002) , have been underway for many years worldwide, especially in the European Union (EU). These efforts have been accelerated by the enforcement of the 7 th Amendment to the Cosmetics Directive and of EU regulations for the registration, evaluation and authorization of chemicals (REACH). Investigation of various in vitro/ex vivo test systems showed that the best results were achieved by a system using a three-dimensional reconstructed human skin model (Botham et al., 1998; Fentem et al., 2001) . The European Centre for the Validation of Alternative Methods (ECVAM) therefore evaluated two human epidermal models, EPISKIN (SkinEthics, Nice, France) and EpiDerm (MatTek, Ashland, MA, USA), during a prevalidation study of in vitro skin irritation tests during 2000 -2001 (Fentem et al., 2001 Zuang et al., 2002) . However, since the predictive performance of the two models in the ECVAM prevalidation study did not meet the acceptance criteria set by the Management Team, further investigations were required to improve the test protocols (Zuang et al., 2002) . Subsequently, during 2003 Subsequently, during -2004 a common protocol for the in vitro evaluation of skin irritation potential was developed, optimized and allowed to proceed to a formal ECVAM validation study (Cotovio et al., 2005; Kandárová et al., 2004) . As a result of the study, an in vitro test protocol using the EpiSkin reconstructed human epidermal model has been scientifically validated as the standalone method of distinguishing skin irritants from non-irritants according to the EU classification. Furthermore, the performance standards for applying a human skin model to in vitro skin irritation have been documented based on the validated test methods (ECVAM SIVS, 2007) . The ECVAM performance standards can then be used to evaluate the accuracy and reliability of other analogous test methods, also known -ciples and measures or to predict the same biological or toxic effect. Recently, the evaluation and the validation of other culture skin models, such as RHE (SkinEthics) and the Leiden reconstructed human epidermal model (Leiden University, Leiden, Netherlands) have been evaluated by using the common protocol according to this performance standard (Kandárová et al., 2006; El et al., 2008) .
In the present study, we investigated whether LabCyte EPI-MODEL, a new in vitro reconstructed human epidermis model, produced by Japan Tissue Engineering Co., Ltd. (Aichi, Japan) was able to reliably identify skin irritant and non-irritant substances, and evaluated whether it could therefore be a candidate for replacing the rabbit Draize test for skin irritation.
MATERIALS AND METHODS

Reconstructed human cultured epidermal model
LabCyte EPI-MODEL is a new, commercially available reconstructed human cultured epidermal model produced by Japan Tissue Engineering Co., Ltd. (Aichi, Japan). It consists of normal human epidermal keratinocytes whose biological origin is neonate foreskin. In order to expand human keratinocytes while maintaining their phenotype, they were cultured with 3T3-J2 cells as a feeder layer (Rheinwald and Green, 1975; Green, 1978) . Reconstruction of human cultured epidermis is achieved substrate (surface 0.3 cm 2 ) at the air-liquid interface for 13 days with an optimized medium containing 5% fetal bovine serum. It constructs a multilayer structure consisting of a fully differentiated epithelium with features of the normal human epidermis, including a stratum corneum. LabCyte EPI-MODEL is embedded in an agarose gel containing nutrient solution and shipped in 24-well plates at around 18°C.
Morphology
parafolmaldehyde and 2% sucrose in 0.1 M phosphatebuffered saline (PBS) (pH 7.4) for more than three hr and processed for embedding in paraffin. Five-micrometer vertical sections were cut and stained with hematoxylin and eosin for light-microscopic examination.
Evaluation of barrier function (IC50 assay)
To evaluate whether the stratum corneum in the epidermal models resists the rapid penetration of the cytotoxic marker chemical sodium lauryl sulfate (SLS; SigmaAldrich, St Louis, MO, USA), viability of epidermis tissue was estimated in terms of the half maximal inhibitory concentration (IC50). Various concentrations of SLS cell viability was assessed at 18 hr. The epidermal models were then washed with PBS and subjected to an MTT assay (Mosman, 1983) . All experiments were performed in triplicate.
Test chemicals
The 20 reference test chemicals (ten non-irritants, ten irritants) described in the ECVAM performance standards are listed in Table 1 . In this study, 19 chemicals (ten nonirritants, nine irritants) from the list were used because tri-isobuthyl phosphate (No. 13) is not available in Japan.
Protocol of skin irritation test with LabCyte EPI-MODEL
LabCyte EPI-MODEL tissues were shipped from the supplier on Mondays and delivered to recipients on Tuesdays. Upon receipt, the tissues were aseptically removed from the transport agarose medium, transferred into 24-well plates (BD Biosciences, San Jose, CA, USA) with the assay medium (0.5 ml) and incubated overnight (37°C, 5%, CO 2 tissues were topically exposed to the test chemicals. Liq--ids (25 mg) were applied from microtubes and moistened -tly spread over the surface of the epidermis with a microspatula. Viscous liquids were applied by using a cell-saver-type tip with a micropipette. Each test chemical was applied to three tissues. In addition, three tissues servwater, and three tissues serving as positive controls were exposed to 5% SLS. After 15 min of exposure, each tissue was carefully rinsed with PBS (Invitrogen, Carlsbad, CA, USA) ten times by using a washing bottle to remove any remaining test chemical from the surface. The blotted tissues were then transferred to new wells of 24-well plates containing 1 ml of fresh assay medium.
The treated and control tissues were post-incubated for 42 hr (37°C, 5%, CO 2 42-hr post-incubation period was completed, blotted tissues were transferred to new wells of 24-well plates containing 0.5 ml of freshly prepared MTT medium (1 mg/ ml; Dojindo Co., Kumamoto, Japan) for MTT assay and conditioned medium was collected for analysis of inter--ed for three hr (37°C, 5% CO 2 and were then transferred to microtubes containing 0.3 ml isopropanol, completely immersing the tissue. Formazan extraction was performed at room temperature and the tissues allowed to stand overnight. Subsequently, 200-μl extracts were transferred to a 96-well plate. The optical density was measured at 570 nm and at 650 nm as a reference absorbance, with isopropanol as a blank.
The tissue viability was calculated as a percentage relative to the viability of negative controls. The mean of the three values from identically treated tissues was used to classify a chemical according to the prediction model.
-ELISA kit (Invitrogen), according to the detailed instructions of the manufacturer.
Prediction model of skin irritation
In this study, the prediction model of skin irritation potential with LabCyte EPI-MODEL was set to refer to the conditions for EpiSkin described in the ECVAM performance standards. This prediction model is described in Table 2 . In the event that the three independent results within an individual batch were not in agreement, the result that occurred twice was used.
RESULTS
Structure of LabCyte EPI-MODEL
The epidermal morphology of LabCyte EPI-MODEL was evaluated by using hematoxylin and eosin staining. Keratinocytes had attached to the surface of the micro- porous membrane, proliferated, and differentiated fully into epidermis (Fig. 1) . The epidermis of LabCyte-EPI-MODEL consisted of multiple and viable cell layers and contained a stratum basal, stratum spinosum, stratum granulosum, and a stratum corneum, similar to the structure of native human epidermis (Fig. 1) .
Barrier function of LabCyte EPI-MODEL
To evaluate whether the stratum corneum of LabCyte EPI-MODEL resists the rapid penetration of certain cytotoxic chemicals, we examined the IC50 value. After various concentrations (from 0.1% to 0.5%) of SLS were applied for 18 hr, the SLS concentration required to reduce tissue viability by 50% (IC50) was measured. As shown in Table 3 , the mean ± S.D. of the IC50 from the evaluation of 25 continuous batches of LabCyte EPI--ation of IC50 was 10.5%. These results indicate that LabCyte EPI-MODEL has a proper skin barrier that resists rapid penetration of the test chemicals in this study.
Assessment of the performance of LabCyte EPI-MODEL for the skin irritation test
Nineteen test chemicals were tested by using LabCyte EPI-MODEL and the common protocol described in the ECVAM performance standard. Three independent runs were performed on different batches of LabCyte EPI-MODEL, with three tissues per test chemical (Table 1 ). In the group of nine irritants, negative predictions for three chemicals, hexyl salicylate (No. 11), 1-bromohexane (No. 16) and di-n-propyl disulphide (No. 18), were not concordant with the results of the in vivo 4). In the group of ten non-irritants, two chemicals, 1-bromo-4-chlorobutane (No. 1) and 4-methyl-thio-benzal-EPI-MODEL (Table 4 ). Summarizing the above data, the sensitivity and specificity of predictions with LabCyte EPI-MODEL were 66.7% and 80% under the skin irritation protocol described in the ECVAM performance standard (Table 5 ). The overall accuracy was 73.7% (Table 5) .
irritant potential
Dermal irritation is the production of reversible dam- No. Vol. 34 No. 3 assay to predict the irritation potential of the test chemmedium from tissues onto which the chemicals were assay results. In this assay, 1-bromohexane (No. 16) was -irritant in the MTT assay (Table 4 ). Summarizing the above data, the sensitivity and spe-6). The overall accuracy was 78.9% (Table 6 ).
DISCUSSION
LabCyte EPI-MODEL has already been characterized in terms such as its tissue structure, lipid composition and barrier function by using light (Fig. 1 ) and electron microscopy (data not shown), immunohistochemistry (data not shown) and reduction of MTT assay. In addition, its application to in-house skin irritation tests such as screening levels has been examined. As no investigation had been carried out concerning whether LabCyte EPI-MODEL could be applied to the common protocol of the skin irritation test described in the ECVAM performance standards, in this study we investigated the prediction performance for skin irritation by using Labcyte EPI-MODEL according to the common protocol.
According to the ECVAM performance standards, a skin model must have a proper barrier function to be used for the skin irritation test; that is, its stratum corthe rapid penetration of cytotoxic marker chemicals such as SLS or Triton X-100. This property can be estimated either by determination of the IC50 of marker chemthe exposure time required to reduce cell viability by 50% (ET50) upon application of the marker chemical at a application for 18 hr was measured in 25 batches of LabCyte EPI-MODEL and was shown to be 2.57 ± 0.27 mg/ ml. The mean IC50 for the approved EpiSkin model validated by ECVAM in the same manner as above is 2.32 function of LabCyte EPI-MODEL is nearly equal to that of EpiSkin and therefore meets the requirement described use as an epidermal model for skin irritation testing. The aim of this study was to evaluate whether the commonly used irritation protocols described in the ECVAM performance standards were applicable to LabCyte EPI-MODEL. To compare the performances of LabCyte EPI-MODEL and EpiSkin we tested the 19 test chemicals described in the ECVAM performance standards. The results showed that LabCyte EPI-MODEL consistently predicted 1-bromo-4-chlorobutane (No. 1) and 4-methylthio-benzaldehyde (No. 7) as irritants, which is consistent with results with EpiSkin. These chemicals are in -cals, hexyl salicylate (No. 11), 1-bromohexane (No. 16), and di-n-propyl disulphide (No.18), were falsely predicted. Similar results for hexyl salicylate and di-n-propyl disulphide were obtained with EpiSkin. It was interesting that the prediction for 1-bromohexane toxicity differed between LabCyte EPI-MODEL and EpiSkin. This chemical was under-predicted as non-irritant by LabCyte EPI-MODEL, whereas EpiSkin models classified it in concordance with in vivo rabbit data. These different predictions probably were due to different characteristics of the stratum corneum in the two in vitro skin models.
As demonstrated in a previous study (Spielmann et al, -port the viability assay. In their validation study EpiSkin assay only); however, the combination of the MTT and of LabCyte EPI-MODEL, the sensitivity was improved from 66.7% to 77.8% by the combination of the MTT and --the ECVAM performance standards: the sensitivity of a "me-too" test must be equal to or higher than 70% and Our study concludes that the prediction model for skin irritation using LabCyte EPI-MODEL according to the common protocol meets the acceptance criteria described in the ECVAM performance standards. As the next step, we regard it as indispensable to evaluate the reproducibility between laboratories in terms of the performance prediction of skin irritation using the present methods and LabCyte EPI-MODEL.
